Physician profile
Lauren E Munck
NPI 1528550035
$2,747.35
in general payments reported to CMS, 2019-2025
19 companies · $620 in 2025
The $620 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $126 · 2022: $571 · 2023: $794 · 2024: $637 · 2025: $620.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,051.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,050.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $645.89 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $416.67 | 2022-2025 | |
| Novo Nordisk INC | $350.67 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $338.65 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $156.16 | 2021-2025 | Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.06 | 2022-2025 | Jardiance |
| Astellas Pharma US INC | $131.36 | 2022-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $99.41 | 2022-2024 | |
| Exact Sciences Corporation | $90.23 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $67.89 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Sumitomo Pharma America, INC. | $54.09 | 2025 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $53.43 | 2024-2025 | Rexulti |
| Esperion Therapeutics, INC. | $53.39 | 2022-2025 | Nexletol |
| Amgen INC. | $47.06 | 2024-2025 | Krystexxa, Prolia, Evenity |
| Glaxosmithkline, LLC. | $40.34 | 2023-2024 | Trelegy Ellipta |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $25.20 | 2025 | Yeztugo |
| Takeda Pharmaceuticals U.S.A., INC. | $17.16 | 2022 | |
| Cequr Corporation | $14.25 | 2024 | Cequr Simplicity |
| E.R. Squibb & Sons, L.L.C. | $13.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Munck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.